Shenqi Xingnao Granules ameliorates cognitive impairments and Alzheimer's disease-like pathologies in APP/PS1 mouse model

被引:0
|
作者
Cui-cui Yang [1 ]
Xiao-yu Jia [1 ]
Li Zhang [1 ]
Ya-li Li [1 ]
Zhan-jun Zhang [2 ,3 ]
Lin Li [1 ]
Lan Zhang [1 ]
机构
[1] Department of Pharmacy, Xuanwu Hospital of Capital Medical University, Beijing Institute for Brain Disorders, Beijing Engineering Research Center for Nerve System Drugs,Key Laboratory for Neurodegenerative Diseases of Ministry of Education
[2] State Key Laboratory of Cognitive Neuroscience and Learning & IDG/McGovern Institute for Brain Research, Beijing Normal University
[3] BABRI Centre, Beijing Normal University
关键词
D O I
暂无
中图分类号
R285.5 [中药实验药理];
学科分类号
1008 ;
摘要
Objective:Alzheimer’s disease(AD) is along with cognitive decline due to amyloid-β(Aβ) plaques,tau hyperphospho rylation,and neuron loss.Shenqi Xingnao Granules(SQXN),a traditional Chinese medicine,significantly ameliorated the cognitive function and daily living abilities of patients with AD.However,till date,no study has investigated the mechanism of action of SQXN on AD.The present study aimed to verify the effects of SQXN treatment on cognitive impairments and AD-like pathologies in APP/PS1 mice.Methods:Four-month-old APP/PS1 transgenic(Tg) mice were randomly divided into a model group and SQXN-treated(3.5,7,14 g/kg per day) groups.Learning-memory abilities were determined by Morris water maze and object recognition test.All mice were sacrificed and the brain samples were collected after 75 d.The soluble Aβ contents were detected by Elisa kit;The levels of expression of NeuN,APP,phosphorylated tau and related protein were measured by Western blotting;The inflammation factors were detected by the proinflammatory panel kit.Results:Four-month-old APP/PS1 mice were administered SQXN by oral gavage for 2.5 months.Using the Morris water maze tests and Novel object recognition,we found that SQXN restored behavioral deficits in the experimental group of Tg mice when compared with the controls.SQXN also inhibited neuronal loss(NeuN marker).SQXN treatment decreased soluble Aβ42 through inhibiting the expression of sAPPβ and BACE-1 without regulating full-length amyloid precursor protein(FL APP).Insulin degrading enzyme(IDE),the Aβ degrading enzyme,were increased by SQXN.In addition,SQXN reduced hyperphosphorylated tau protein levels and prevented excessive activation of p-GSK-3β in the brain of APP/PS1 mice.Compared with APP/PS1 transgenic negative mice,IFN-γ,IL-1β,IL-2,IL-4,IL-5,IL-6,IL-12 p70,KC/GRO and TNF-α were not obviously changed in the brain of 6.5-month-old APP/PS1 transgenic(Tg) mice.However,SQXN could inhibited the expression of IL-2.Conclusion:These results demonstrate that SQXN ameliorates the cognitive impairments in APP/PS1 mice.The possible mechanisms involve its inhibition of neuronal loss,soluble Aβ deposition,tau hyperphosphorylation and inflammation.
引用
收藏
页码:421 / 429
页数:9
相关论文
共 50 条
  • [41] Humulus japonicus inhibits the progression of Alzheimer's disease in a APP/PS1 transgenic mouse model
    Park, Tae-Shin
    Ryu, Young-Kyoung
    Park, Hye-Yeon
    Kim, Jae Yun
    Go, Jun
    Noh, Jung-Ran
    Kim, Yong-Hoon
    Hwang, Jung Hwan
    Choi, Dong-Hee
    Oh, Won-Keun
    Lee, Chul-Ho
    Kim, Kyoung-Shim
    INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, 2017, 39 (01) : 21 - 30
  • [42] Diffusion Kurtosis Imaging to Detect Amyloidosis in an APP/PS1 Mouse Model for Alzheimer's Disease
    Vanhoutte, Greetje
    Pereson, Sandra
    Delgado y Palacios, Rafael
    Guns, Pieter-Jan
    Asselbergh, Bob
    Veraart, Jelle
    Sijbers, Jan
    Verhoye, Marleen
    Van Broeckhoven, Christine
    Van der Linden, Annemie
    MAGNETIC RESONANCE IN MEDICINE, 2013, 69 (04) : 1115 - 1121
  • [43] Alterations of the proteolytic and proteasomal enzymes in the retina in APP/PS1 mouse model of Alzheimer's disease
    Pushpitha, Kanishka
    Mirzaei, Mehdi
    Chitranshi, Nitin
    Rajput, Rashi
    Graham, Stuart L.
    Gupta, Vivek Kumar
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
  • [44] Neuroprotective effects of resistance physical exercise on the APP/PS1 mouse model of Alzheimer's disease
    Campos, Henrique Correia
    Ribeiro, Deidiane Elisa
    Hashiguchi, Debora
    Glaser, Talita
    Milanis, Milena da Silva
    Gimenes, Christiane
    Suchecki, Deborah
    Arida, Ricardo Mario
    Ulrich, Henning
    Monteiro Longo, Beatriz
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [45] Aβ deposition and related pathology in an APP x PS1 transgenic mouse model of Alzheimer's disease
    Howlett, D. R.
    Bowler, K.
    Soden, P. E.
    Riddell, D.
    Davis, J. B.
    Richardson, J. C.
    HISTOLOGY AND HISTOPATHOLOGY, 2008, 23 (01) : 67 - 76
  • [46] INTRANASAL DELIVERY OF INCRETIN RECEPTOR AGONISTS IN THE APP/PS1 MOUSE MODEL OF ALZHEIMER'S DISEASE
    Abdulhameed, N.
    Babin, A.
    Hansen, K.
    Banks, W.
    Talbot, K.
    Rhea, E.
    JOURNAL OF INVESTIGATIVE MEDICINE, 2024, 72 (01) : 679 - 680
  • [47] Increased Alzheimer's disease-like pathology in the APP/PS1ΔE9 mouse model lacking Nrf2 through modulation of autophagy
    Joshi, Gururaj
    Gan, Kok Ann
    Johnson, Delinda A.
    Johnson, Jeffrey A.
    NEUROBIOLOGY OF AGING, 2015, 36 (02) : 664 - 679
  • [48] Parishin A ameliorates cognitive decline by promoting PS1 autophagy in Alzheimer's disease
    Guo, Song
    Yi, Lilin
    Luo, Man
    Dong, Zhifang
    Du, Yehong
    FRONTIERS IN AGING NEUROSCIENCE, 2025, 17
  • [49] Alterations in expression and localization of POMGNT1 in the APP/PS1 mouse model of Alzheimer's disease
    Jiang, Hanxiao
    Feng, Yuxue
    Hao, Xia
    He, Guiqiong
    Li, Xiaofeng
    GENES & DISEASES, 2024, 11 (05)
  • [50] Tetrahydroxy Stilbene Glucoside Ameliorates Cognitive Impairments and Pathology in APP/PS1 Transgenic Mice
    Gao, Dan
    Chen, Chen
    Huang, Rui
    Yang, Cui-cui
    Miao, Bei-bei
    Li, Lin
    Zhang, Lan
    CURRENT MEDICAL SCIENCE, 2021, 41 (02) : 279 - 286